SLC22A4 and chronic myelogenous leukemia, BCR-ABL1 positive: reported that polymorphisms in OCTN1 and OCTN2 transporter genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumors treated with imatinib therapy, which was also confirmed in CML therapy.